Furthermore, in vivo studies utilizing established animal models of PAH, wherein LGALS3BP is modulated via genetic or pharmacological approaches, would be invaluable for validating its causal role and therapeutic potential. Here, LGALS3BP is linked to pulmonary arterial hypertension.